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Although we normally think of dendritic cells (DCs; ref-
erences 1 and 2) as the “initiators” of immune responses and
of their activity as confined largely to interaction with naive
T cells in secondary lymphoid organs, there is emerging ev-
idence that DCs are also important players in the effector
phase of the immune response. Although rare, DCs form a
dense network of cells in many tissues such as skin and re-
spiratory and intestinal mucosa. This strategic location en-
ables DCs to efficiently take up antigen and interact with
 
effector CD4
 
 
 
 T cells in tissues to trigger cytokine secre-
tion and activate local immune responses. Thus, we could
envisage DCs in tissues as a true sentinel system with a dual
mission: to alert T cells in the lymph node and trigger local
defense reactions in nonlymphoid tissues. Although imma-
ture DCs, such as those in tissues, express MHC class II
mainly in intracellular compartments, local inflammation
causes rapid formation of MHC class II–antigen complexes
and their transport to the cell membrane, and also increases
expression of costimulatory molecules (3).
Similarly to the situation for CD4
 
 
 
 T cells, DCs can be-
come activators of effector CTLs during CD8
 
 
 
 T cell re-
sponses. Immature DCs, with their high phagocytic capac-
ity, would be able to efficiently take up fragments from
dying infected cells or even infectious virus and cross-
present it via MHC class I (1, 2). It is important to consider
that these antigen-loaded DCs would also become easy tar-
gets of activated CTLs, which require only a handful of
MHC I–antigen complexes in order to activate their cyto-
toxic machinery. Several recently published experiments
indicate that this can indeed be the case. When allogeneic
DCs, or DCs pulsed with MHC class I–binding peptides,
were injected into naive or immune hosts, they were rap-
idly eliminated by a CD8
 
 
 
 T cell–dependent mechanism
(4–7). In a more physiological situation, systemic infection
with a DC-tropic strain of LCMV was shown to result in a
dramatic depletion of DCs from the spleens of infected an-
imals and development of severe immune suppression (8).
While the ability of DCs to act as stimulators of CD4
 
 
 
effector T cells is clearly advantageous to the immune re-
sponse, it is less obvious what benefits to the immune re-
sponse or the host would arise from CTL-mediated killing
of DCs. In all cases where DCs are not virus reservoirs,
their elimination would not help clear infection but would
deplete the immune system of critically important cells. On
the other hand, killing of DCs by CTLs could occur at a
stage when further presentation of antigen is unnecessary,
or could contribute to the downregulation of the immune
response to prevent excessive CTL activation. In support of
this latter possibility, recent reports have implicated per-
forin in the regulation of CD8
 
 
 
 T cell clonal burst size.
Perforin is a critical component of the CTL lytic granule,
and its inactivation greatly blunts the cytotoxic activity of
CD8
 
 
 
 T cells and NK cells leading to impaired viral clear-
ance and ineffective tumor surveillance (9). In mice, per-
forin deficiency is also associated with enhanced accumula-
tion of antigen-specific CD8
 
 
 
 T cells after viral or bacterial
infection, and after DC immunization (10, 11). In humans,
perforin gene defects are observed in patients with Familial
Hemophagocytic Lymphohistiocytosis, a lymphoprolifera-
tive syndrome with accumulation of activated CD8
 
 
 
 T
cells (12). There is so far no direct evidence that the en-
hanced accumulation of activated CD8
 
 
 
 T cells in perforin
deficiencies is causally linked to DC elimination by CTLs,
and other mechanisms remain possible. However, DC
elimination in vivo has been found to be perforin depen-
dent (reference 4 and unpublished data) although other
studies have not confirmed this finding (7). As an additional
piece of evidence in favor of the association of dysregulated
T cell immune responses with enhanced DC survival, the
loss of DC sensitivity to TNF-related apoptosis-inducing
ligand–induced cell death has been reported in two cases of
human Autoimmune Lymphoproliferative Syndrome (13).
In conclusion, several lines of indirect evidence suggest that
DC elimination is an important requirement for the regula-
tion of CD8
 
 
 
 T cell responses, and for the homeostasis of
immune responses in general.
 
There are additional situations where killing of DCs may
 
be an important factor in shaping the CD8
 
 
 
 T cell immune
response. In the course of viral infections, DCs presenting
several viral antigens simultaneously may not be able to effi-
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ciently initiate immune responses to each of them, if some
of those antigens are recognized by preexisting effector
CTLs, or if CTLs of one specificity develop much faster
than the others. This may be the case in the well recognized
phenomenon of “original antigenic sin,” where an existing
immune response prevents the initiation of a later, cross-
reactive but independent immune response. This phenome-
non has been reported long ago for antiviral antibody re-
sponses (14, 15), and more recently for antiviral CD8
 
 
 
 T
cell immune responses (16). One likely mechanism by
which the inhibition could take place is through the elimi-
nation of DCs presenting novel viral antigens by the preex-
isting pool of cross-reactive CTLs (17). Removal of DCs
presenting specific antigen also represents a potential setback
in immunotherapy protocols where repeated DC adminis-
trations are used to induce and maintain CTL immune re-
sponses to tumors. Once a CTL response is established, any
DCs injected to boost the response are rapidly eliminated
without being able to induce further expansion of specific
CD8
 
 
 
 T cells, and with little apparent effect on the immune
response (unpublished data). Thus, the DCs that can effi-
ciently initiate a CD8
 
 
 
 immune responses have limited re-
stimulatory ability due to their susceptibility to CTL attack.
One paper in this issue (18) adds several new pieces of
information to this picture and offers a solution to the
problem of rescuing DCs from CTL killing. Medema et al.
have used DC cultures and transfection experiments to
convincingly demonstrate that activation of DCs by
CD40L or LPS renders DCs resistant to the in vitro cyto-
toxic activity of CTLs. This is due to the expression in DCs
of a serine protease inhibitor (SPI)-6 (PI-9 in humans),
which is already known to immunologists for its ability to
induce resistance to lysis in effector CTLs. SPI-6 acts by in-
hibiting the function of one critical component in CTL
granules, granzyme B, which activates caspase-dependent
DNA fragmentation causing apoptosis of target cells. As a
second important observation, the authors report that resis-
tance to CTL lysis can be induced efficiently by Th1 cells,
but not by Th2 cells. This appears to be due to the com-
bined action of Th2 cytokines, with IL-10 being one criti-
cal, but not unique, factor in this process. The overall result
is that DCs that have been “helped” by antigen-specific
Th1 cells become resistant to T cell lysis, while DCs
“helped” by Th2 cells do not.
These results are certainly elegant and provocative but
are restricted to an in vitro system. We can only speculate
about the extent to which SPI-6 expression will affect DC
survival and the immune response. For example, the life
span of DCs in vivo is not known, and it is possible that the
survival of activated DCs may be intrinsically limited.
Thus, protection of activated DCs from CTL attack may
not significantly extend their life span. Alternatively, DCs
exposed to CTL action for an extended time in vivo may
undergo eventual cell death that is not apparent in vitro
due to the different time frame of the experiment. At the
same time, we must recognize that tightly regulated re-
sponses such as those described by Medema et al. are likely
to be activated for a purpose, and that small differences in
DC survival have the potential to have considerable effects
on the resulting immune responses through successive
rounds of amplification. Thus, as we eagerly await the re-
sults of in vivo experiments, we can speculate on how pro-
tecting DCs from being killed may affect different stages of
the T cell immune response (Fig. 1).
One first and rather obvious consequence of enhanced
DC survival would be the amplification of CD8
 
 
 
 T cell
Figure 1. Killing of DCs may
regulate the clonal expansion of an-
tigen-specific CD8  T cells. Naive
CD8  T cells (N) interact with anti-
gen-presenting DCs and are induced
to proliferate and differentiate into
killer (K) and memory (M) progeny.
(A) DCs that are susceptible to the
lytic activity of CTLs are eliminated,
preventing the further activation of
memory cells. This may serve as a
negative feedback mechanism to
limit the immune response. How-
ever, the net result may also be that
T cell expansion is insufficient to
provide an effective response. (B)
DCs that are resistant to killing by
CD8  T cells will remain available
for T cell recognition and induce
further activation and clonal expan-
sion of memory T cells. However,
without the negative regulation pro-
vided by DC elimination, excessive
accumulation of activated CD8  T
cells may result. DCs may also be
susceptible to killing by NK cells
(not shown in Fig.). This could have
an impact on both primary and sec-
ondary immune responses. 
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immune responses. Protecting DCs from being killed
would be one additional mechanism by which T cell help
can amplify CTL responses, together with the expression of
costimulatory molecules through CD40–CD40L interac-
tion, and the promotion of DC survival through CD40L
and TNF-related activation-induced cytokine expression
(1, 2). All these mechanisms would ensure that DCs remain
available for longer to allow CD8
 
 
 
 T cell recognition. The
authors consider this possibility when they discuss the dif-
ferential induction of SPI-6 by Th1 and Th2 cells. Th2
cells are not normally associated with the activation of
CD8
 
 
 
 T cells, and the observation that Th2 cells do not
protect DCs from being killed could offer a mechanism for
why this may be the case.
The regulation of CD8
 
 
 
 T cell activation and clonal ex-
pansion appears to be controlled by a variety of factors. The
contribution of T cell help has been long recognized as a
critical parameter, and the lack of T cell help has been
shown to result in abortive CD8
 
 
 
 T cell proliferation and
T cell anergy (19, 20). In contrast, the recognition of anti-
gen in a suitable context results in the onset of a large num-
ber of cycles of proliferation, which do not require the
continued presence of antigen and APCs (21, 22). Re-
markably, the time of contact between naive CD8
 
 
 
 T cells
and APCs that is necessary to initiate cell division is re-
ported as being only 2 h. After this brief contact, T cells re-
quire a further 24 to 48 h to initiate cell division. When ac-
quisition of CTL effector function was compared with cell
division using the same experimental system, both appeared
to follow a similar set of rules. Again, acquisition of cyto-
toxic function was possible after a naive CD8
 
 
 
 T cell had
been in contact with antigen for 
 
 
 
8 h, but a further 48–72 h
were required for the development of effector function.
These results would suggest that the initiation of a primary
CTL immune response does not require DCs to survive for
an extended period of time. Cognate interaction between
T cells and DCs could easily terminate long before the T
cells have acquired cytotoxic activity, or have completed
clonal expansion, with apparently few long-term effects on
the response. Data obtained in vivo using antigen-pulsed
DCs labeled with a fluorescent tracker are consistent with
those findings. Division of antigen-specific CD8
 
 
 
 T cells is
clearly apparent in the lymph node by 66–72 h. Interest-
ingly, at approximately the same time, DCs carrying anti-
gen disappear from the lymph node, and this is presumably
due to the activation of CTL effector function (5). There-
fore, premature killing of DCs would not preclude the ini-
tiation and completion of T cell clonal expansion, nor
would DC resistance to CTL lysis be expected to improve
it. In this regard, it is also useful to consider that MHC class
I–antigen complexes at the surface of APC decay relatively
rapidly, with a half- life of 
 
 
 
5–10 h (23). Therefore, DCs
are likely to lose the ability to activate naive cells well be-
fore they lose the susceptibility to CTL killing, and their
longer survival is not likely to contribute to further activa-
tion of naive CD8
 
 
 
 T cells.
In contrast to the primary immune response, resistance
of DCs to CTL lysis is likely to have a much greater impact
on secondary immune responses. Resistance would espe-
cially affect the survival of DCs in tissues or spleen, since
effector CTLs have no significant access to the lymph node
(24). Those DCs that are resistant to CTL lysis would be
able to induce further clonal expansion of effector CTL – if
this can occur – or of “central memory cells” in lymphoid
organs. Even partial DCs resistance to CTL lysis would
make a difference in these situations, as previously activated
T cells only require 
 
 
 
1 h of contact with the APCs in or-
der to initiate cell division (25). Eventually, either through
lysis by CTLs or by other mechanisms, DCs would be
eliminated and the response would subside.
One puzzling observation in Medema’s paper is that
SPI-6 expression in DCs is induced not only by CD40
stimulation and cognate interaction with Th1 cells, but also
by treatment with LPS. Why would stimuli as different as
these, one being typical of the innate and one of the adap-
tive immune response, both elicit a similar response in
DCs? Although LPS and CD40L can elicit similar responses
in DCs in some respects (for example, both upregulate co-
stimulatory molecules) their effects are not identical (IL-12
production and help to CD8
 
 
 
 T cells are induced by
CD40L, but poorly or not at all by LPS) or can even be an-
tagonistic (LPS induces DC apoptosis in vivo, and this can
be rescued by CD40L; references 1 and 2). However, both
stimuli signal “true danger” and the presence of either in-
fectious agents, or of foreign antigens that have alerted
CD4
 
 
 
 T cells. We would like to argue that one situation
where DCs do need to become resistant to cell-mediated
lysis is to prevent themselves being killed by NK cells. NK
cells, like CTLs, induce target cell lysis by a mechanism
that involves perforin, granzymes, and granule release, and
that would presumably be inhibited by SPI-6. Several types
of NK cells have been shown to recognize CD80 or CD86
as target antigens (26, 27), although this does not appear to
be dependent on recognition through a receptor such as
CD28 or CTLA-4. Recognition of CD80 or CD86 is suf-
ficient to elicit lysis of DCs, or other activated APCs, in
vitro despite their expression of high levels of MHC class I
molecules. A common feature of LPS and CD40 is their
ability to activate immature DCs to high expression of co-
stimulatory molecules, thereby making them potentially
more susceptible to NK cell–mediated lysis. It has not been
formally shown whether lysis by NK cells is an important
mechanism in the regulation of DC survival in vivo, as the
above observations would suggest. If it is, it would appear
critical for DCs to upregulate defense mechanisms such as
SPI-6 expression in order to initiate adaptive immune re-
sponses. Indeed it has been reported that maturation de-
creases the susceptibility of DCs to NK cell–mediated lysis
(28), despite the concomitant increase in “target” costimu-
latory molecules. If resistance to NK lysis is an important
mechanism, other stimuli that induce upregulation of
CD80 and CD86 on DCs could also be expected to acti-
vate SPI-6 expression.
Clearly, there is a lot more that needs to be known be-
fore we can decide whether killing of DCs, whether by
CTLs or NK cells, is an important mechanism in regulating 
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in vivo immune responses, or just another trick by viruses
and other infectious agents to thwart immune attack. We
also need to understand to what extent these mechanisms
are activated in different DC subpopulations, and how each
of these DC subpopulations contributes to the regulation of
immune responses. Nonetheless, the observation that DCs
take the effort to protect themselves from CTL or NK cell
attack suggests that killing of DCs is an important regula-
tory mechanism, and that DCs may remain in control of
the immune response even from their deathbed.
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